Long intergenic non-protein coding RNA 1133 (LINC01133)

Long intergenic non-protein coding RNA 1133 (LINC01133) is a long non-coding RNA (lncRNA) located on chromosome 1q32.2, transcribed from an intergenic region and producing multiple transcript isoforms[3][7]. It does not code for protein but regulates gene expression through diverse mechanisms, including acting as a competing endogenous RNA, binding DNA, RNA, or RNA-binding proteins, and modulating chromatin status[1][7]. LINC01133 plays dual roles in cancer biology, functioning as either an oncogene or a tumor suppressor depending on tissue and tumor context. It regulates critical processes such as cell proliferation, migration, invasion, and the epithelial-mesenchymal transition (EMT), often through interaction with chromatin-modifying complexes (such as PRC2/EZH2) and by acting as a microRNA sponge[1][7]. Clinically, aberrant expression of LINC01133 has been linked to tumorigenesis, progression, and prognosis in multiple cancer types, supporting its use as a prognostic biomarker and potential therapeutic target in oncology[1][5][7]. Key context: LINC01133 is not a classical drug target (e.g., enzyme or receptor) but an RNA molecule that influences cancer progression, making it a *potential* therapeutic target primarily in the context of RNA interference or similar approaches[7]. There are no approved drugs directly targeting LINC01133 as of the current knowledge base; its value currently lies in its biomarkers and regulatory role[7]. Known for context-dependent effects (tumor suppressor or oncogene), which presents both opportunities and challenges for clinical translation[7].

Other names

lncRNA-PAGBCprognosis-associated gallbladder cancer lncRNALINC01133